Related Experiment Video
Updated: Jan 14, 2026
Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Evaluating the impact of obstructive sleep apnea-hypopnea syndrome on irritable bowel syndrome
Guangqin Wu1, Yanfei Fang1, Yu Hong2
1Department of Gastroenterology, Taicang Affiliated Hospital of Soochow University, Suzhou, 215400, China.
Background:
Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder; recently, hypoxia has emerged as a potential contributor to IBS. This study aimed to examine the impact of obstructive sleep apnea-hypopnea syndrome (OSA) on IBS.
Methods:
582 patients were enrolled and categorized into IBS (n = 84) and non-IBS (n = 498) groups based on diagnostic criteria. Associations between OSA and IBS were analyzed. For patients with OSA and combined IBS receiving continuous positive airway pressure (CPAP) therapy, IBS Severity Scoring System (IBS-SSS) scores were compared before and after treatment.
Results:
Patients in the IBS group exhibited significantly higher apnea-hypopnea index (AHI) than that in the non-IBS group (median 12 vs. 18, P = 0.002). IBS-SSS scores were significantly elevated in the AHI>30 group compared to the AHI≤15 group (median 220 vs. 180, P = 0.002) and in the moderate-to-severe hypoxia group compared to the no-hypoxia group (median 200 vs. 120, P = 0.008). Multifactorial logistic regression analysis indicated that increasing OSA and hypoxia severity significantly elevated IBS risk (P trend = 0.012, P trend<0.001). A Significant reduction in IBS-SSS scores was observed after 3 and 6 months of CPAP treatment (P = 0.003 for 3 months; P < 0.001 for 6 months).
Conclusions:
OSA was associated with increased IBS risk. In IBS patients, comorbid OSA and hypoxia can worsen symptoms. CPAP therapy was found to ameliorate IBS symptoms in OSA patients.
More Related Videos
04:53Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach
Published on: October 18, 2024
10:37Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Related Concept Videos
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
01:21Drugs for Treatment of Constipation-Predominant IBS
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...